Abrégé

The invention refers to genetic engineering and can be used in biotechnology, medicine, and agriculture for the manufacture of gene therapy products. Gene therapy DNA vector based on the gene therapy DNA vector VTvaflV carrying the therapeutic gene selected from the group of NOS2, NOS3, VIP, KCNMA1, and CGRP genes is constructed in order to increase the expression level of this therapeutic gene in humans and animals, while gene therapy DNA vector VTvafl7-NOS2, or VTvaflV-NOS3, or VTvafl7-VIP, or VTvafl7-KCNMAI, or VTvafl7-CGRP has the nucleotide sequence SEQ ID No. 1, or SEQ ID No. 2, or SEQ ID No. 3, or SEQ ID No. 4, or SEQ ID No. 5, respectively.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 38/22 - Hormones
• A61K 38/26 - Glucagons
• A61K 38/44 - Oxydoréductases (1)
• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales

Abrégé

The invention refers to genetic engineering and can be used in biotechnology, medicine, and agriculture for the manufacture of gene therapy products. Gene therapy DNA vector based on the gene therapy DNA vector VTvaf 17 carrying the therapeutic gene selected from the group of BDNF, VEGFA, BFGF, NGF, GDNF, NT3, CNTF, and IGF1 genes was constructed in order to increase the expression level of this therapeutic gene in humans and animals, while gene therapy DNA vector VTvaf17-BDNF, or VTvaf 17-VEGFA, or VTvaf17-BFGF, or VTvaf17-NGF, or VTvaf17-GDNF, or VTvaf17-NT3, or VTvaf17-CNTF, or VTvaf17-IGFl, has the nucleotide sequence SEQ ID No. 1, or SEQ ID No. 2, or SEQ ID No. 3, or SEQ ID No. 4, or SEQ ID No. 5, or SEQ ID No. 6, or SEQ ID No. 7, or SEQ ID No. 8, respectively.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
• A61K 38/30 - Facteurs de croissance analogues à l'insuline, c.-à-d. somatomédines, p. ex. IGF-1, IGF-2
• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales

Abrégé

The invention refers to genetic engineering and can be used in biotechnology, medicine, and agriculture for the manufacture of gene therapy products. Gene therapy DNA vector based on the gene therapy DNA vector VTvaf1V carrying the therapeutic gene selected from the group of KRT5, KRT14, LAMB 3, and COL7A1 genes was constructed in order to increase the expression level of this therapeutic gene in humans and animals, while gene therapy DNA vector VTvaf17-KRT5, or VTvaf17-KRT14, or VTvaf17-LAMB3, or VTvaf17-COL7A1 has the nucleotide sequence SEQ ID No. 1, or SEQ ID No. 2, or SEQ ID No. 3, or SEQ ID No. 4, respectively. The gene therapy DNA vector contains no nucleotide sequences of viral origin and no antibiotic resistance genes, which ensures its safe use for gene therapy in humans and animals. A method of obtaining the specified vector, the use of the vector, a strain of Escherichia coli carrying the specified vector, and a method of industrial production of the specified vector are also provided.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C07K 14/78 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine ou globuline insoluble à froid [CIG]
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales

Abrégé

The invention refers to genetic engineering and can be used in biotechnology, medicine, and agriculture for the manufacture of gene therapy products. A gene therapy DNA vector based on the VTvaf1V gene therapy DNA vector is proposed that carries a target gene selected from the group of genes ANG, ANGPT1, VEGFA, FGF1, HIF1a, HGF, SDF1, KFK4, PDGFC, PROK1, PROK2, to increase the expression level of this target gene in humans and animals. Gene therapy DNA vector VTvaf17-ANG or VTvaf 17-AN GPT 1 or VTvaf17-VEGFA or VTvaf17-FGF1 or VTvaf17-HIF1a or VTvaf17-HGF or VTvaf17-SDF1 or VTvaf 17-KFK4 or VTvaf 17-PDGFC, or VTvaf 17-PDKFC or VTvaf17 has the nucleotide sequence of SEQ ID No. 1 or SEQ ID No. 2 or SEQ ID No. 3 or SEQ ID No. 4 or SEQ ID No. 5 or SEQ ID No. 6 or SEQ ID No. 7 or SEQ ID No. 8 or SEQ ID No. 9 or SEQ ID No. 10 or SEQ ID No. 11, respectively. Also provided are a method of producing said vector, the use of a vector, a strain of Escherichia coli carrying said vector, as well as a method of industrial production of said vector.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
• A61K 38/46 - Hydrolases (3)
• A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales

Abrégé

A gene therapy DNA vector based on the VTvaf17 gene therapy DNA vector carrying a target gene selected from the group of genes COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN, PLOD1 to increase the expression level of this target gene in humans and animals. Moreover, the gene therapy DNA vector VTvaf17-COL1A1 or VTvaf17-COL1A2 or VTvaf17-P4HA1 or VTvaf17-P4HA2 or VTvaf17-COL7A1 or VTvaf17-CLCA2 or VTvaf17-ELN or VTvaf17-PLOD1 has the nucleotide sequence SEQ ID NO. SEQ ID No. 3 or SEQ ID No. 4 or SEQ ID No. 5 or SEQ ID No. 6 or SEQ ID No. 7 or SEQ ID No. 8, respectively. The DNA vector contains no nucleotide sequences of viral origin and no antibiotic resistance genes, providing the possibility of its safe use for genetic therapy in humans and animals.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61K 38/39 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine, globuline insoluble à froid [CIG]
• A61K 38/44 - Oxydoréductases (1)
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales

Abrégé

The invention refers to genetic engineering and can be used in biotechnology, medicine, and agriculture for the manufacture of gene therapy products. A gene therapy DNA vector based on the VTvaf17 gene therapy DNA vector is proposed that carries a target gene selected from the group of SHH, CTNNB1, NOG, WNT7A genes for the treatment of diseases characterized by impaired tissue regeneration, wound healing, growth, pigmentation and hair coloring, formation and maturation of hair follicles, processes of differentiation and growth of cells, leading to a decrease in the activity of hair follicles, including with allopecia, autoimmune diseases, hereditary and acquired pathological conditions thawing, and for accelerated healing of wounds, restoration of the hairline and the prevention and inhibition of alopecia. Moreover, the gene therapy DNA vector VTvaf17-SHH, or VTvaf 17 -CTNNB 1, or VTvaf17-NOG, or VTvaf17-WNT7A has the nucleotide sequence of SEQ ID No. 1 or SEQ ID No. 2 or SEQ ID No. 3 or SEQ ID No. 4, respectively. Also provided are a method of producing said vector, the use of a vector, a strain of Escherichia coli carrying said vector, as well as a method of industrial production of said vector.

Classes IPC  ?

• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
• C12N 1/20 - BactériesLeurs milieux de culture

Abrégé

Escherichia coli strain SCS110-AF/VTvaf17-COL1A1, SCS110-AF/VTvaf17-COL1A2, SCS110-AF/VTvaf17-BMP2 or SCS110-AF/VTvaf17-BMP7 obtains by the method described above carrying gene therapy DNA vector VTvaf17-COL1A1, VTvaf17-COL1A2, VTvaf17-BMP2 or VTvaf17-BMP7. The method of producing the gene therapy DNA vector carrying COL1A1, or COL1A2, or BMP2, or BMP7 therapeutic gene uses on an industrial scale.

Classes IPC  ?

• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique

Abrégé

The invention is related to genetic engineering and can be used in biotechnology, medical science and agriculture to create plant varieties, including transgenic ones. The invention is a gene therapy DNA vector VTvafl7-Actl-Cas9 based on the gene therapy DNA vector VTvaflV carrying the Cas9 therapeutic gene for the heterologous expression of this therapeutic gene in the plant cells during the editing of plant genomes, while the gene therapy DNA vector VTvafl7-Actl-Cas9 has the nucleotide sequence SEQ ID No. 1. The invention can be used in editing of plant genomes in the plant cells.

Classes IPC  ?

• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C12R 1/19 - Escherichia coli

Abrégé

The invention refers to genetic engineering and can be used in biotechnology, medicine, and agriculture for the manufacture of gene therapy products. A gene therapy DNA vector based on the VTvaflV gene therapy DNA vector is proposed that carries a target gene selected from the group of genes ANG, ANGPT1, VEGFA, FGF1, HIFla, HGF, SDF1, KFK4, PDGFC, PROK1, PROK2, to increase the expression level of this target gene in humans and animals. Gene therapy DNA vector VTvafl7-ANG or VTvaf 17- AN GPT 1 or VTvafl7-VEGFA or VTvafl7-FGFl or VTvafl7-HIFla or VTvafl7-HGF or VTvafl7-SDFl or VTvaf 17-KFK4 or VTvaf 17-PDGFC, or VTvaf 17-PDKFC or VTvafl7 has the nucleotide sequence of SEQ ID No. 1 or SEQ ID No. 2 or SEQ ID No. 3 or SEQ ID No. 4 or SEQ ID No. 5 or SEQ ID No. 6 or SEQ ID No. 7 or SEQ ID No. 8 or SEQ ID No. 9 or SEQ ID No. 10 or SEQ ID No. 11, respectively. Also provided are a method of producing said vector, the use of a vector, a strain of Escherichia coli carrying said vector, as well as a method of industrial production of said vector.

Classes IPC  ?

• C12N 15/12 - Gènes codant pour des protéines animales
• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C12R 1/19 - Escherichia coli

Abrégé

The invention is related to genetic engineering and can be used in biotechnology, medical science and agriculture to create gene therapy medicinal products. Gene therapy DNA vector based on the VTvaflV gene therapy DNA vector is proposed, the vector carrying the target Cas9 gene for heterologous expression of this target gene in human and animal cells upon implementation of various genome editing methods. Gene therapy DNA vector VTvafl7-Cas9 having a nucleotide sequence SEQ ID No. 1. Gene therapy DNA vector based on gene therapy DNA vector VTvaflV carrying the Cas9 target gene, said DNA vector is unique due to the fact that the constructed gene therapy DNA vector VTvafl7-Cas9, due to the limited size of VTvafl7 vector part not exceeding 3200 bp, has the ability to efficiently penetrate into human and animal cells and express the Cas9 target gene cloned to it. A method of production of the specified vector, the method of usage of the vector, Escherichia coli strain carrying the specified vector, as well as a method of production of the specified vector on an industrial scale are also provided.

Classes IPC  ?

• C12N 15/12 - Gènes codant pour des protéines animales
• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C12R 1/19 - Escherichia coli

Abrégé

The invention refers to genetic engineering and can be used in biotechnology, medicine, and agriculture for the manufacture of gene therapy products. Gene therapy DNA vector based on the gene therapy DNA vector VTvaflV carrying the therapeutic gene selected from the group of KRT5, KRT14, LAMB 3, and COL7A1 genes was constructed in order to increase the expression level of this therapeutic gene in humans and animals, while gene therapy DNA vector VTvafl7-KRT5, or VTvafl7-KRTl4, or VTvafl7-LAMB3, or VTvafl7-COL7Al has the nucleotide sequence SEQ ID No. 1, or SEQ ID No. 2, or SEQ ID No. 3, or SEQ ID No. 4, respectively. The gene therapy DNA vector contains no nucleotide sequences of viral origin and no antibiotic resistance genes, which ensures its safe use for gene therapy in humans and animals. A method of obtaining the specified vector, the use of the vector, a strain of Escherichia coli carrying the specified vector, and a method of industrial production of the specified vector are also provided.

Classes IPC  ?

• C12N 15/12 - Gènes codant pour des protéines animales
• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C12R 1/19 - Escherichia coli

Abrégé

A gene therapy DNA vector based on the VTvafl 7 gene therapy DNA vector carrying a target gene selected from the group of genes COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN, PLOD1 to increase the expression level of this target gene in humans and animals. Moreover, the gene therapy DNA vector VT vaf 17 -COL 1 A 1 or VTvafl7-COLlA2 or VTvafl 7-P4HA1 or VTvafl 7-P4HA2 or VTvafl7-COL7Al or VTvafl7-CLCA2 or VTvafl 7-ELN or VTvafl 7-PLOD 1 has the nucleotide sequence SEQ ID NO. SEQ ID No. 3 or SEQ ID No. 4 or SEQ ID No. 5 or SEQ ID No. 6 or SEQ ID No. 7 or SEQ ID No. 8, respectively. The DNA vector contains no nucleotide sequences of viral origin and no antibiotic resistance genes, providing the possibility of its safe use for genetic therapy in humans and animals.

Classes IPC  ?

• C12N 15/12 - Gènes codant pour des protéines animales
• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C12R 1/19 - Escherichia coli

Abrégé

The invention is related to genetic engineering and can be used in biotechnology, medical science and agriculture to create gene therapy medicinal products. Gene therapy DNA vector based on gene therapy DNA vector VTvaflV carrying the target gene selected from a group of genes comprising BMP-2, BMP- 7, OPG, PDGFA, PDGFB to increase the expression level of this target gene In humans and animals is suggested. Wherein, gene therapy DNA vector VTvafl7-BMP-2, or VTvafl7-BMP-7, or VTvafl7-OPG, or VTvafl7-PDGFA, or VTvafl7-PDGFB has nucleotide sequence SEQ ID No. 1 or SEQ ID No. 2 or SEQ ID No. 3 or SEQ ID No. 4 or SEQ ID No. 5, respectively. The gene therapy DNA vector does not contain nucleotide sequences of viral origin and there are no antibiotic resistance genes, providing the possibility of its safe use for genetic therapy in humans and animals. A method of production of the specified vector, the method of use of the vector, Escherichia coli strain carrying the specified vector, as well as a method of production of the specified vector on an industrial scale are also suggested.

Classes IPC  ?

• C12N 15/12 - Gènes codant pour des protéines animales
• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C12R 1/19 - Escherichia coli

Abrégé

The invention refers to genetic engineering and can be used in biotechnology, medicine, and agriculture for the manufacture of gene therapy products. A gene therapy DNA vector based on the VTvaf17 gene therapy DNA vector is proposed that carries a target gene selected from the group of SHH, CTNNB1, NOG, WNT7A genes for the treatment of diseases characterized by impaired tissue regeneration, wound healing, growth, pigmentation and hair coloring, formation and maturation of hair follicles, processes of differentiation and growth of cells, leading to a decrease in the activity of hair follicles, including with allopecia, autoimmune diseases, hereditary and acquired pathological conditions thawing, and for accelerated healing of wounds, restoration of the hairline and the prevention and inhibition of alopecia. Moreover, the gene therapy DNA vector VTvafl7-SHH, or VTvaf 17 -CTNNB 1, or VTvaf17-NOG, or VTvaf17-WNT7A has the nucleotide sequence of SEQ ID No. 1 or SEQ ID No. 2 or SEQ ID No. 3 or SEQ ID No. 4, respectively. Also provided are a method of producing said vector, the use of a vector, a strain of Escherichia coli carrying said vector, as well as a method of industrial production of said vector.

Classes IPC  ?

• C12N 15/12 - Gènes codant pour des protéines animales
• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C12R 1/19 - Escherichia coli

Abrégé

The invention refers to genetic engineering and can be used in biotechnology, medicine, and agriculture for the manufacture of gene therapy products. Gene therapy DNA vector based on the gene therapy DNA vector VTvaflV carrying the therapeutic gene selected from the group of NOS2, NOS3, VIP, KCNMA1, and CGRP genes is constructed in order to increase the expression level of this therapeutic gene in humans and animals, while gene therapy DNA vector VTvafl7-NOS2, or VTvaflV- NOS3, or VTvafl7-VIP, or VTvafl7-KCNMAl, or VTvafl7-CGRP has the nucleotide sequence SEQ ID No. 1, or SEQ ID No. 2, or SEQ ID No. 3, or SEQ ID No. 4, or SEQ ID No. 5, respectively. Each of the constructed gene therapy DNA vectors, namely VTvafl7-NOS2, or VTvafl7-NOS3, or VTvafl7-VIP, or VTvafl7-KCNMAl, or VTvafl7-CGRP has the ability to efficiently penetrate into cells and express the therapeutic gene selected from the group of NOS2, NOS3, VIP, KCNMA1, and CGRP genes, respectively, and cloned to it due to the limited size of VTvafl7 vector part not exceeding 3200 bp. The gene therapy DNA vector contains no nucleotide sequences of viral origin and no antibiotic resistance genes, which ensures its safe use for gene therapy in humans and animals.

Classes IPC  ?

• C12N 15/12 - Gènes codant pour des protéines animales
• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C12R 1/19 - Escherichia coli

Abrégé

Escherichia coliEscherichia coli strain SCSI 10- AF carrying the vector, a method of industrial production of the vector are proposed.

Classes IPC  ?

• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
• C12N 1/20 - BactériesLeurs milieux de culture
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques

Abrégé

The invention refers to genetic engineering and can be used in biotechnology, medicine, and agriculture for the manufacture of gene therapy products. Gene therapy DNA vector based on the gene therapy DNA vector VTvaf 17 carrying the therapeutic gene selected from the group of BDNF, VEGFA, BFGF, NGF, GDNF, NT3, CNTF, and IGF1 genes was constructed in order to increase the expression level of this therapeutic gene in humans and animals, while gene therapy DNA vector VTvafl7-BDNF, or VTvaf 17- VEGFA, or VTvafl7-BFGF, or VTvafl7-NGF, or VTvafl7-GDNF, or VTvafl7-NT3, or VTvafl7-CNTF, or VTvafl7-IGFl, has the nucleotide sequence SEQ ID No. 1, or SEQ ID No. 2, or SEQ ID No. 3, or SEQ ID No. 4, or SEQ ID No. 5, or SEQ ID No. 6, or SEQ ID No. 7, or SEQ ID No. 8, respectively. Each of the constructed gene therapy DNA vectors, namely VTvafl7-BDNF, or VTvaf 17- VEGFA, or VTvafl7-BFGF, or VTvafl7-NGF, or VTvafl7-GDNF, or VTvafl7-NT3, or VTvafl7- CNTF, or VTvafl7-IGFl has the ability to efficiently penetrate into cells and express the therapeutic gene selected from the group of BDNF, VEGFA, BFGF, NGF, GDNF, NT3, CNTF, and IGF1 genes, respectively, and cloned to it due to the limited size of VTvaf 17 vector part not exceeding 3200 bp. The gene therapy DNA vector contains no nucleotide sequences of viral origin and no antibiotic resistance genes, which ensures its safe use for gene therapy in humans and animals.

Classes IPC  ?

• C12N 15/12 - Gènes codant pour des protéines animales
• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C12R 1/19 - Escherichia coli

Abrégé

Escherichia coliEscherichia coli strain carrying the vector, a method of industrial production of the vector are proposed.

Classes IPC  ?

• C12N 15/12 - Gènes codant pour des protéines animales
• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C12R 1/19 - Escherichia coli

Abrégé

The invention refers to genetic engineering and can be used in biotechnology, medicine, and agriculture for the manufacture of gene therapy products. The specified purpose is achieved by using gene therapy DNA vectors are created based on gene therapy DNA vector VTvaflV for the treatment of diseases featuring disruption of blastocyst adhesion, attachment, implantation, and apposition mechanism, female infertility development caused by endometrium failure during the blastocyst implantation period, including during the in vitro fertilization procedures, via the increase of the expression of IL11, LIT, DICER, HOXA10, or WT1 therapeutic genes in humans and animals.

Classes IPC  ?

• C12N 15/12 - Gènes codant pour des protéines animales
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
• C12R 1/19 - Escherichia coli

Abrégé

The invention refers to genetic engineering. The gene therapy DNA vector VTvaf17-BMP-2 contains the coding region of BMP-2 therapeutic gene, cloned to the gene therapy DNA vector VTvaf17 with the nucleotide sequence SEQ ID No. 1, the gene therapy DNA vector VTvaf17-BMP-7 contains the coding region of BMP-7 therapeutic gene, cloned to the gene therapy DNA vector VTvaf17 with the nucleotide sequence SEQ ID No. 2, the gene therapy DNA vector VTvaf17-LMP-1 contains the coding region of LMP-1 therapeutic gene, cloned to the gene therapy DNA vector VTvaf17 with the nucleotide sequence SEQ ID No. 3, the gene therapy DNA vector VTvaf17-NELL-1 contains the coding region of NELL- 1 therapeutic gene, cloned to the gene therapy DNA vector VTvaf17 with the nucleotide sequence SEQ ID No. 4.

Classes IPC  ?

• C12N 15/12 - Gènes codant pour des protéines animales
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
• C12Q 1/686 - Réaction en chaine par polymérase [PCR]
• C12R 1/19 - Escherichia coli

Abrégé

Produced the gene therapy DNA vectors based on the gene therapy DNA vector for treatment of diseases associated with disorders of osteogenesis, formation and regeneration of bone and cartilage tissues, including, in case of bone fractures, increased brittleness of bones, reduction of bones mineralisation, for improvement in osteoinduction of bone implants. The gene therapy DNA vector contains the coding region of the COL1A1, COL1A2, BMP2 or BMP7 therapeutic genes. Methods of producing or use the gene therapy DNA vector carrying therapeutic genes. Escherichia coli strain SCS110-AF/VTvaf17-COL1A1, SCS110-AF/VTvaf17-COL1A2, SCS110-AF/VTvaf17-BMP2 or SCS110-AF/VTvaf17-BMP7 obtains by the method described above carrying gene therapy DNA vector VTvaf17-COL1A1, VTvaf17-COL1A2, VTvaf17-BMP2 or VTvaf17-BMP7. The method of producing the gene therapy DNA vector carrying COL1A1, or COL1A2, or BMP2, or BMP7 therapeutic gene uses on an industrial scale.

Classes IPC  ?

• C12N 15/12 - Gènes codant pour des protéines animales
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
• C12R 1/19 - Escherichia coli

Abrégé

Produced the gene therapy DNA vectors based on the gene therapy DNA vector VTvaf17 for the treatment of diseases featuring disruption of mucociliary transport, mucolytic function and development of mucostasis, including cystic fibrosis. The gene therapy DNA vector contains the coding region of the SKI, TGFB3, TIMP2 or FMOD therapeutic genes. Methods of producing or use a gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying SKI, TGFB3, TIMP2 or FMOD therapeutic genes. The methods of producing strain for production of gene therapy DNA vector for treatment of diseases featuring disruption of mucociliary transport, mucolytic function and development of mucostasis. Escherichia coli strain SCS 110-AF/VTvaf17-SKI, SCS 110-AF/VTvaf17-TGFB3, SCS110-AF/VTvaf17- TIMP2 or SCS110-AF/VTvaf17- FMOD obtains by the method described above carrying gene therapy DNA vector VTvaf17-SKI, VTvaf17-TGFB3, VTvaf17-TIMP2 or VTvaf17- FMOD. The method of producing a gene therapy DNA vector carrying SKI, TGFB3, TIMP2 or FMOD therapeutic gene uses on an industrial scale.

Classes IPC  ?

• C12N 15/12 - Gènes codant pour des protéines animales
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
• C12R 1/19 - Escherichia coli

Abrégé

Gene -therapeutic DNA vectors based on the VTvaf17 gene-therapeutic DNA vector have been created for the treatment of diseases characterized by impaired mucociliary transport and mucolytic function and the development of mucostasis, including cystic fibrosis. The gene therapy DNA vector contains the coding region of the CFTR therapeutic gene, or the NOS1 therapeutic gene, or the AQ1 therapeutic gene, or the AQ3 therapeutic gene, or the AQ5 therapeutic gene. Methods for their preparation or use are proposed, as well as strains for the production of a gene therapy vector.

Classes IPC  ?

• C12N 15/12 - Gènes codant pour des protéines animales
• C12N 15/53 - Oxydoréductases (1)
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli

Abrégé

Escherichia coliEscherichia coliEscherichia colisacBcatRrecAEscherichia coliEscherichia coliEscherichiacoliEscherichiacolicoli strain SCS110-AF and subjecting these cells to electroporation with gene therapy DNA vector VTvaf17. After that, the cells are poured into agar plates (Petri dishes) with a selective medium containing yeastrel, peptone, 6% sucrose, and 10 µg/ml of chloramphenicol.

Classes IPC  ?

• C12N 15/09 - Technologie d'ADN recombinant
• C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique

Abrégé

The invention relates to medicine. A method of correcting pathological human skin conditions related to aging includes a preliminary evaluation of a person's skin, selecting material, cultivating cells, separating a fibroblast culture, and separating cell material, wherein a first portion of the fibroblast culture is sent to be studied, and a second portion of the fibroblast culture is stored. The fibroblast culture is then analyzed by determining a DNA sequence and gene activity, the obtained results are compared to data from a standard group, and abnormalities in the fibroblast genome are identified. On the basis of the obtained genetic research data, a conclusion is made regarding a link between the identified abnormalities in the structure and/or function of a gene and changes in the patient's skin. Genetic constructs are created containing cDNA of those genes of the patient which exhibit altered activity or the DNA structure of which shows abnormalities in the patient, said constructs providing said genes with the structure and function of normal genes; the genetic constructs are introduced into a culture of the patient's fibroblasts, and modified autologous fibroblasts are then administered to the patient.

Classes IPC  ?

• A61K 35/36 - PeauSystème pileuxOnglesGlandes sébacéesCérumenÉpidermeCellules épithélialesKératinocytesCellules de LangerhansCellules ectodermiques
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques

Abrégé

The invention relates to heat engineering and can be used in heat-exchange apparatuses. A heat-exchange apparatus, consisting of a single component, is formed by extrusion as a tubular body with external and internal radial branches, wherein identical longitudinal circular openings are formed around the circumference, and at least one mount is formed on the external surface of the tubular body. The technical result is the possibility, with a simple design, of using a large quantity of different heat-transfer agents.

Classes IPC  ?

• F28D 7/16 - Appareils échangeurs de chaleur comportant des ensembles de canalisations tubulaires fixes pour les deux sources de potentiel calorifique, ces sources étant en contact chacune avec un côté de la paroi d'une canalisation les canalisations étant espacées parallèlement
• F28F 1/42 - Éléments tubulaires ou leurs ensembles avec moyens pour augmenter la surface de transfert de chaleur, p. ex. avec des ailettes, avec des saillies, avec des évidements les moyens étant à la fois à l'extérieur et à l'intérieur de l'élément tubulaire

Abrégé

The invention relates to means for cooling thermally loaded components, for example of LED lamps. The device has a profiled structure and comprises a base and, integral thereto, branched radiators, namely a central radiator and lateral radiators that are disposed at a distance from one another to the left and right of the central radiator, wherein the end of the central radiator opposite the base is provided with a protuberance having a shaped longitudinal groove, and the outer contours of the lateral surfaces of all of the radiators are a similar shape and are designed on the basis of a double-branch principle, whereby each of the radiators is provided with lateral primary branches and, extending therefrom, secondary branches, which are also profiled. In all of the solutions, the contours of the surfaces of the lateral primary and secondary branches of all of the left-hand radiators are similar to the contours of the surfaces of the lateral primary and secondary branches of all of the right-hand radiators. The technical result is an increase in cooling efficiency as a result of a greater heat emitting surface.

Classes IPC  ?

• G12B 15/06 - Refroidissement par contact avec des masses absorbantes ou rayonnantes de la chaleur, p. ex. bain réfrigérant
• F21V 29/00 - Protection des dispositifs d'éclairage contre les détériorations thermiquesDispositions de refroidissement ou de chauffage spécialement adaptées aux dispositifs ou systèmes d'éclairage
• H05K 7/20 - Modifications en vue de faciliter la réfrigération, l'aération ou le chauffage
• G06F 1/20 - Moyens de refroidissement
• H01L 23/367 - Refroidissement facilité par la forme du dispositif
• F28F 3/04 - Éléments ou leurs ensembles avec moyens pour augmenter la surface de transfert de chaleur, p. ex. avec des ailettes, avec des évidements, avec des ondulations les moyens faisant partie intégrante de l'élément

Abrégé

The modular light-emitting diode luminaire relates to tubeless lighting engineering devices based on light-emitting diodes. Said luminaire comprises a base, a printed circuit board, at least one light-emitting diode arranged on the printed circuit board, an optical element, a heat-dissipating device, and a box with a power supply unit, a control circuit unit and electrical connecting elements, wherein the heat-dissipating device consists of a substrate, which simultaneously acts as the base of the heat-dissipating device, wherein the printed circuit board and the optical element are positioned on one side of the substrate, and heat-dissipating radiators with a special shape are positioned on the opposite side, wherein the central heat-dissipating radiator and the outermost heat-dissipating radiators are formed integrally with the substrate, wherein the base is in the form of a rectangle and has projections around the edges of each lateral side, wherein the lower part of the projections is intended for fixing the printed circuit board and the optical element, the upper part of the projections is formed by the outermost heat-dissipating radiators, and the lateral parts of the projections are equipped with longitudinal irregularly shaped grooves, wherein the central heat-dissipating radiator has, at the end and on the side opposite the substrate, a widened portion with an open longitudinal irregularly shaped groove provided in the center thereof.

Classes IPC  ?

• F21S 4/00 - Dispositifs ou systèmes d'éclairage utilisant une guirlande ou une bande de sources lumineuses
• F21Y 101/02 - Structure miniature, p. ex. diodes électroluminescentes (LED)
• F21V 29/00 - Protection des dispositifs d'éclairage contre les détériorations thermiquesDispositions de refroidissement ou de chauffage spécialement adaptées aux dispositifs ou systèmes d'éclairage